It was on these grounds, that we formed the hypothesis that the imipridone ONC201/TIC10, which was shown before to be more potent in c-myc high expressing glioblastomas (Ishida et al., 2018), might have a pronounced anti-medulloblastoma efficacy in this subtype. The gene discussed is MYC; the disease is medulloblastoma.